Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Pipeline Review, H2 2016


  • Products Id :- GMDHC0458TDB
  • |
  • Pages: 59
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Pipeline Review, H2 2016', provides in depth analysis on Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted pipeline therapeutics.

The report provides comprehensive information on the Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)

The report reviews Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics and enlists all their major and minor projects

The report assesses Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Overview 7

Therapeutics Development 8

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Products under Development by Stage of Development 8

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Products under Development by Therapy Area 9

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Products under Development by Indication 10

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Products under Development by Companies 13

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Companies Involved in Therapeutics Development 22

AngioChem Inc. 22

ArmaGen Inc. 23

Bioasis Technologies Inc. 24

Green Cross Corporation 25

JCR Pharmaceuticals Co., Ltd. 26

Laboratorios Del Dr. Esteve S.A. 27

RegenxBio Inc. 28

Sangamo BioSciences, Inc. 29

Shire Plc 30

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Drug Profiles 31

AGT-182-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

EGT-301-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

idursulfase-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

idursulfase beta-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

JR-032-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

JR-141-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

MTf-I2S-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

MTfp-I2S-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

RGX-121-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

SB-913-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)-Featured News & Press Releases 47

Jul 14, 2016: ArmaGen Presents Data from First Cohort of Phase 1/2a of AGT-182 for Treatment of Hunter Syndrome 47

Jul 05, 2016: REGENXBIO Provides Update On Gene Therapy Development Program RGX-121 48

Jun 20, 2016: Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II 48

Apr 19, 2016: Preclinical Data from REGENXBIO's RGX-121 Gene Therapy Program to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting 49

Feb 25, 2016: ESTEVE Provides Update On EGT-301 For Hunter Syndrome 50

Jul 31, 2015: biOasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome 51

Jun 23, 2015: ACTSI-supports first-in-man clinical trial for Hunter syndrome at Emory University Hospital 51

Jun 15, 2015: ArmaGen Achieves Clinical Milestone in Hunter Syndrome Collaboration with Shire 52

Mar 10, 2015: PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen's investigational enzyme replacement therapy, AGT-182, for Phase 1 Clinical Trial 53

Jan 26, 2015: Shire's Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation for the Treatment of Neurocognitive Decline Associated with Hunter Syndrome 54

Dec 11, 2014: ArmaGen Announces FDA Acceptance of IND Application for AGT-182 for the Treatment of Hunter Syndrome 54

Sep 18, 2014: biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation 55

Jun 17, 2014: ArmaGen Receives Notice of Allowance for U.S. Patent Covering Novel Investigational Therapy for Hunter Syndrome 56

Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria 56

Jul 18, 2013: ARMAGEN Receives US Orphan Designation For Lead Product AGT-182 57

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by AngioChem Inc., H2 2016 22

Pipeline by ArmaGen Inc., H2 2016 23

Pipeline by Bioasis Technologies Inc., H2 2016 24

Pipeline by Green Cross Corporation, H2 2016 25

Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2016 26

Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 27

Pipeline by RegenxBio Inc., H2 2016 28

Pipeline by Sangamo BioSciences, Inc., H2 2016 29

Pipeline by Shire Plc, H2 2016 30

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AngioChem Inc.

ArmaGen Inc.

Bioasis Technologies Inc.

Green Cross Corporation

JCR Pharmaceuticals Co., Ltd.

Laboratorios Del Dr. Esteve S.A.

RegenxBio Inc.

Sangamo BioSciences, Inc.

Shire Plc

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Therapeutic Products under Development, Key Players in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Therapeutics, Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Pipeline Overview, Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Pipeline, Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Pipeline Assessment

select a license
Single User License
USD 3500 INR 251650
Site License
USD 7000 INR 503300
Corporate User License
USD 10500 INR 754950

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com